Bellicum Pharmaceuticals Provides Operational Update and Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2018
Bellicum Pharmaceuticals, Inc. (BLCM)
Last bellicum pharmaceuticals, inc. earnings: 3/12 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.bellicum.com/investor-overview
Company Research
Source: GlobeNewswire
HOUSTON, March 12, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today reported financial results for the fourth quarter and full year ended December 31, 2018. “We believe that Bellicum is well-positioned for an exciting and eventful 2019 as a result of our investments to strengthen our clinical development and executive teams over the past 24 months,” said Bellicum’s President & CEO Rick Fair. “Based on promising preclinical and initial clinical data on BPX-601, we have prioritized GoCAR-T® candidates incorporating our iMC activation switch in our clinical development strategy. In addition to progressing our Phase 1/2 trial of BPX-601, we intend to submit IND applications for two novel, dual-switch GoCAR-T clinical programs in 2019. For rivo-cel™, we anticipate topline Phase 2 results in pediatric patients in the second quarter of 2019, whi
Show less
Read more
Impact Snapshot
Event Time:
BLCM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BLCM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BLCM alerts
High impacting Bellicum Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
BLCM
News
- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
BLCM
Sec Filings
- 3/1/24 - Form 15-12G
- 2/27/24 - Form EFFECT
- 2/27/24 - Form EFFECT
- BLCM's page on the SEC website